

What is claimed is:

1. A composition having a protein of interest purified from mammalian cells, surfactant and a residual amount of sialate o-acetylsterase, wherein the residual amount of sialate o-acetylsterase is less than about 5 ppm.
2. The composition of claim 1, wherein the surfactant is polysorbate 20.
3. The composition of claim 1, wherein the mammalian cells include CHO cells.
4. The composition of claim 3, wherein the CHO cells include SIAE-knockout CHO cell.
5. The composition of claim 2, wherein the sialate o-acetylsterase causes degradation of the polysorbate 20.
6. The composition of claim 1, wherein the composition is a parenteral formulation
7. The composition of claim 2, wherein a concentration of the polysorbate in the composition is about 0.01 %w/v to about 0.2% w/v.
8. The composition of claim 1, wherein the protein of interest is selected from a group consisting of a monoclonal antibody, a polyclonal antibody, a bispecific antibody, an antibody fragment and an antibody-drug complex.
9. The composition of claim 1 further comprising one or more pharmaceutically acceptable excipients.
10. The composition of claim 1 further comprising a buffer selected from a group consisting of histidine buffer, citrate buffer, alginate buffer, and arginine buffer.
11. The composition of claim 1 further comprising a tonicity modifier.
12. The composition of claim 1 further comprising sodium phosphate.
13. The composition of claim 1, wherein concentration of the protein of interest is about 20 mg/mL to about 400 mg/mL.
14. The composition of claim 1, wherein the sialate o-acetylsterase is CHO-sialate o-acetylsterase.
15. The composition of claim 1, wherein the sialate o-acetylsterase is cytosolic sialic acid esterase isoform.
16. The composition of claim 1, wherein the sialate o-acetylsterase is lysosomal sialic acid esterase isoform.